Lupin has launched Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. The company’s alliance partner Concord Biotech (Concord) had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation. This tablet is indicated for Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant and use in combination with cyclosporine and corticosteroids.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.